Sanofi-Synthelabo's REACH Registry launched to increase knowledge of atherothrombosis

Published: 2004-01-27 06:56:00

Updated: 2004-01-27 06:56:00

Sanofi-Synthelabo announced recently the launch of the REACH (REduction of Atherothrombosis for Continued Health) Registry, one of the largest international registries ever conducted in people at risk of atherothrombosis, a life-threatening disease process that can lead to heart attack and stroke...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK